Brief: Adaptive Biotechnologies Announces FDA Acceptance Of Genentech’S Investigational New Drug Application For The First Neoantigen-Directed T-Cell Therapy Product In Oncology

Adaptive Biotechnologies

09/05/2023 12:34

May 9 (Reuters) - Adaptive Biotechnologies Corp
 ADPT.O :
    * ADAPTIVE BIOTECHNOLOGIES ANNOUNCES FDA ACCEPTANCE OF
GENENTECH’S
INVESTIGATIONAL NEW DRUG APPLICATION FOR THE FIRST
NEOANTIGEN-DIRECTED T-CELL THERAPY PRODUCT IN ONCOLOGY
    * ADAPTIVE BIOTECHNOLOGIES CORP- UNDER DEAL, GENENTECH TO DO
CLINICAL, REGULATORY, COMMERCIALIZATION EFFORTS FOR ANY T-CELL
THERAPY PRODUCT CANDIDATE
    * ADAPTIVE BIOTECHNOLOGIES CORP - REITERATES ITS FULL YEAR
REVENUE
GUIDANCE IN RANGE OF $205 TO $215 MILLION

Source text for Eikon:  ID:nGNXbp6NV8 
Further company coverage:  ADPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))